Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (VCYT) announced that Afirma thyroid test research will be presented at the American Thyroid Association meeting November 4–7, 2026. The Philadelphia conference will feature 10 abstracts, comprising two oral presentations and eight posters; five studies were conducted independently of Veracyte.
Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets. Posters explore preoperative diagnosis, cancer recurrence risk and long-term outcomes following molecular testing, including research using Veracyte’s GRID database. The research examines how gene expression may inform thyroid nodule diagnosis and assessment of cancer aggressiveness.
Veracyte (VCYT) will participate in three investor conferences in November, with fireside chats available through live audio webcasts.
The chats are scheduled for UBS in Palm Beach Gardens on November 10 at 4:15 p.m. Eastern Time; Jefferies in London on November 18 at 2:30 p.m. Greenwich Mean Time; and Stephens in Nashville on November 19 at 9:30 a.m. Central Time. Webcast replays will remain available for 90 days after each presentation.
Veracyte (Nasdaq: VCYT) announced Phase III trial analysis results linking Decipher Prostate scores to benefit from adding abiraterone in very high-risk nonmetastatic prostate cancer.
The retrospective STAMPEDE analysis included 401 patients receiving androgen deprivation therapy, which lowers androgen levels, alone or with abiraterone. The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01). At five years, absolute reductions in distant metastasis events with added abiraterone were 10% for high scores, 11% for very high scores and 2% for lower scores. Higher scores were associated with worse survival outcomes. A separate analysis of over 27,000 real-world patients supported Decipher’s ability to assess prognosis, not predict abiraterone benefit. Findings will be presented at ESMO on October 24, 2026.
Veracyte (Nasdaq: VCYT) announced six studies involving its genomic tests will be presented at ESMO 2026, October 23–27 in Madrid.
The presentations cover prostate and bladder cancer treatment selection and risk assessment, plus breast cancer health economics. Veracyte said a Decipher Prostate oral presentation will provide the first evidence that the test predicts benefit from adding abiraterone to androgen deprivation therapy for clinically very high-risk, nonmetastatic prostate cancer. A separate late-breaking oral presentation will report a two-year, within-trial economic analysis of Prosigna-guided chemotherapy decisions in the Phase III OPTIMA breast cancer trial. Four posters address additional prostate and bladder cancer research.
Veracyte (Nasdaq: VCYT) secured Medicare coverage for its Prosigna Breast Risk of Recurrence test, effective August 19, 2026.
Coverage through Palmetto GBA’s MolDX program applies to postmenopausal women with early-stage estrogen receptor positive breast cancer who meet Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes. Following the test’s June 2026 U.S. launch, Veracyte expects reimbursement to support broader adoption. Prosigna estimates the risk of breast cancer recurring over 10 years. The independent phase III OPTIMA trial demonstrated that Prosigna-guided treatment could spare chemotherapy for more than two-thirds of patients with clinically high-risk breast cancer without compromising outcomes.
Veracyte (Nasdaq: VCYT) will release its third-quarter 2026 financial results after the market closes on November 4, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the results and provide a general business update. A webcast replay will be available on the company’s website after the live broadcast.
Veracyte (VCYT) reported that a phase III trial analysis found its Decipher Prostate test predicts benefit from adding hormone therapy to radiation. The retrospective analysis examined short-term androgen deprivation therapy (ADT) in men with intermediate-risk prostate cancer. A treatment-by-Decipher interaction for distant metastasis was statistically significant (p<0.001).
Among patients with intermediate or high Decipher scores, adding ADT was associated with an 8% absolute reduction in distant metastasis at 10 years. For the 44% with low scores, the difference was 1 percentage point and was not statistically significant. Higher scores were also independently associated with greater risk of biochemical failure, distant metastasis and prostate-specific mortality. Researchers analyzed samples from 395 of the trial’s 1,492 participants, with a median follow-up of 10.2 years. A separate phase III study of Decipher-guided treatment changes completed enrollment earlier this year.
Veracyte (VCYT) announced eight Decipher-focused studies slated for presentation at ASTRO 2026 in Boston.
Six oral presentations, including a quick-pitch session, and two posters are scheduled during the September 26–30 meeting. The studies use the Decipher Prostate Genomic Classifier test and whole-transcriptome data. They include analyses from Phase II and III clinical trials, GRID research and national real-world studies. Topics include assessing prostate cancer progression risk and identifying patients who may benefit from adding androgen-deprivation therapy to radiation.
Veracyte (VCYT) has acquired Convergent Genomics, adding the UroAmp urinary tumor DNA (utDNA) testing platform to its urology diagnostics portfolio.
UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC) for therapy-response monitoring and post-treatment surveillance, with supporting data from nine peer-reviewed publications and over 40 posters and abstracts. Veracyte plans an initial UroAmp-based test to help determine which patients completing Bacillus Calmette-Guerin (BCG) induction therapy are likely to benefit from maintenance treatment, with commercialization expected in late 2028, subject to reimbursement timelines.
The deal includes $150 million in upfront cash and up to $30 million in milestone-based cash tied to UroAmp reimbursement efforts. Veracyte does not expect the ongoing Convergent operating expenses to change its previously issued 2026 adjusted EBITDA guidance.
Veracyte (Nasdaq: VCYT) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time. A live audio webcast and a 90-day replay will be accessible via the company’s investor relations website.